About 6,750 results

ALLMedicine™ Hepatic Encephalopathy Center

Research & Reviews  2,115 results

An outbreak of Amanita exitialis poisoning.
Clinical Toxicology (Philadelphia, Pa.); Meng H, Chen Z et. al.

Mar 16th, 2023 - The mushroom Amanita exitialis is reported to cause acute liver injury. It is found in Southern China, and has been previously associated with a high incidence of mortality. We described a series of 10 patients with Amanita exitialis poisoning adm...

Ferrous sulfate reverses cerebral metabolic abnormality induced by minimal hepatic ence...
Metabolic Brain Disease; Liu XF, Lu JJ et. al.

Mar 15th, 2023 - Orally administered ferrous iron was previously reported to significantly improve the cognition and locomotion of patients with minimal hepatic encephalopathy (MHE). However, the metabolic mechanisms of the therapeutic effect of ferrous iron are u...

Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis a...
Liver International : Official Journal of the Internation... Turco L, Reiberger T et. al.

Mar 11th, 2023 - Portal hypertension (PH) is the most common complication of cirrhosis and represents the main driver of hepatic decompensation. The overarching goal of PH treatments in patients with compensated cirrhosis is to the reduce the risk of hepatic decom...

Serum ammonia does not guide management and is over utilised in patients with cirrhosis...
Internal Medicine Journal; Hannah N, Vasic D et. al.

Mar 10th, 2023 - Hepatic encephalopathy is a confusional state associated with cirrhosis. Serum ammonia levels are neither sensitive nor specific for the diagnosis. We audited the ordering location and hospital unit whilst assessing the impact on management at a m...

Development and validation of a practical prognostic nomogram for evaluating inpatient ...
Annals of Hepatology; Chen J, Luo S et. al.

Mar 9th, 2023 - Cirrhotic patients with acute variceal hemorrhage (AVH) have high short-term mortality. Established prognostic scores are seldom applicable clinically, partially because they need external validation or contain subjective variables. We aimed to de...

see more →

Guidelines  6 results

EASL Clinical Practice Guidelines on the management of hepatic encephalopathy.
Journal of Hepatology; ,

Jun 21st, 2022 - The EASL Clinical Practice Guidelines (CPGs) on the management of hepatic encephalopathy (HE) present evidence-based answers to a set of relevant questions (where possible, formulated in PICO [patient/population, intervention, comparison and outco...

KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy,...
Clinical and Molecular Hepatology;

Jan 11th, 2020 - KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.|2020| ,|

Chinese guidelines on management of hepatic encephalopathy in cirrhosis.
World Journal of Gastroenterology; Xu XY, Ding HG et. al.

Oct 3rd, 2019 - The Chinese Society of Hepatology developed the current guidelines on the management of hepatic encephalopathy in cirrhosis based on the published evidence and the panelists' consensus. The guidelines provided recommendations for the diagnosis and...

Consensus Report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediat...
Biology of Blood and Marrow Transplantation : Journal of ... Ovchinsky N, Frazier W et. al.

Sep 6th, 2017 - Some patients with veno-occlusive disease (VOD) have multiorgan dysfunction, and multiple teams are involved in their daily care in the pediatric intensive care unit. Cardiorespiratory dysfunction is critical in these patients, requiring immediate...

How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and r...
European Journal of Gastroenterology & Hepatology; Shawcross DL, Dunk AA et. al.

Nov 26th, 2015 - Hepatic encephalopathy is defined as brain dysfunction caused by liver insufficiency and/or portosystemic shunting. Symptoms include nonspecific cognitive impairment, personality changes and changes in consciousness. Overt (symptomatic) hepatic en...

see more →

Drugs  38 results see all →

Clinicaltrials.gov  340 results

Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C

Mar 9th, 2023 - Globally, the mortality after any infection in cirrhosis patients is very high. The cumulative mortality in patients with infections was 43.5% (11,987 patients) where as the mortality rate without infection was 13.6% (2317 patients). Over the year...

The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.

Mar 7th, 2023 - This study is being completed for patients with cirrhosis, including patients with a prior history of hepatic encephalopathy (HE) to evaluate the feasibility and benefits of medically-tailored meals as an intervention. Patients will be enrolled fr...

Bilirubin Increases the Risk of Nosocomial Infection in Cirrhotic Patients

Mar 6th, 2023 - Cirrhosis is the 14th most widespread cause of mortality worldwide [1], cirrhosis can take one of the following forms: compensated and decompensated phases [2]. The latter is related to subsequent complications such as ascites, hepatic encephalopa...

Comparing Nifuroxazide Plus Lactulose With Lactulose Alone in the Treatment of Hepatic Encephalopathy

Mar 6th, 2023 - Hepatic Encephalopathy (HE) is a central nervous system dysfunction caused by liver insufficiency and/or portosystemic shunting, manifesting as a wide spectrum of neurological or psychiatric abnormalities characterized by alteration of cognitive a...

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Mar 6th, 2023 - Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in live...

see more →

News  196 results

Onatasertib Plus Toripalimab Elicits Early Responses in Relapsed/Metastatic Cervical Cancer

Nov 17th, 2022 - Onatasertib (ATG-008) plus toripalimab elicited an objective response rate (ORR) of 52.4% in patients with relapsed or metastatic cervical cancer, irrespective of PD-L1 expression, according to preliminary data from the phase 2 TORCH trial (NCT035...

Steroids and G-CSF Improve 90-day Survival in Severe Alcoholic Hepatitis

Nov 9th, 2022 - WASHINGTON — Adding granulocyte-colony stimulating factor (G-CSF) to steroid therapy can improve 90-day survival for patients with severe alcoholic hepatitis (SAH), researchers from India reported. Among patients with SAH, the combination of G-CSF...

Ryan Reynolds' Colonoscopy; NASH Drug Passes Phase II Test; New Drug Target in IBD?

Sep 14th, 2022 - In an effort to shine a light on the importance of colorectal cancer screening, movie-star Ryan Reynolds shared details of his polyp removal found on colonoscopy. (GMA) The phase IIb Harmony study of efruxifermin in non-alcoholic steatohepatitis (...

Decrease in Portal Hepatic Pressure Gradient Related to Shunts

Aug 18th, 2022 - A reduction in portal hepatic pressure gradient (PPG) soon after implantation of a transjugular intrahepatic portosystemic shunt (TIPS) greater than 60% was associated with improved ascites control at 6 weeks in a study published in Hepatology. "T...

Degree of PPG reduction linked with ascites control after TIPS
Carolyn Crist

Aug 17th, 2022 - A reduction in portal hepatic pressure gradient (PPG) soon after implantation of a transjugular intrahepatic portosystemic shunt (TIPS) greater than 60% was associated with improved ascites control at 6 weeks in a study published in Hepatology. “T.

see more →

Patient Education  5 results see all →